Antiviral Drugs - Ivory Coast

Ivory Coast

In Ivory Coast, the revenue in the Antiviral Drugs market is forecasted to reach US$9.17m by the year 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 1.38%, leading to a market volume of US$9.82m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, amounting to US$30,640.00m in 2024.
Ivory Coast's market for antiviral drugs is witnessing a surge in demand due to the increasing prevalence of viral diseases in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Ivory Coast has experienced a steady growth in recent years.

Customer preferences: The increase in the prevalence of viral infections in Ivory Coast has led to an increase in the demand for antiviral drugs. Customers are increasingly seeking affordable and effective antiviral drugs that can treat a wide range of viral infections.

Trends in the market: The Antiviral Drugs market in Ivory Coast is expected to continue to grow due to the increasing prevalence of viral infections, such as HIV/AIDS and hepatitis. The market is also being driven by the increasing availability of antiviral drugs and the growing awareness of the importance of early diagnosis and treatment of viral infections.

Local special circumstances: Ivory Coast has a high prevalence of HIV/AIDS, with an estimated 460,000 people living with the disease. The country also has a high prevalence of hepatitis B and C. These local special circumstances have contributed to the growth of the Antiviral Drugs market in Ivory Coast.

Underlying macroeconomic factors: The growth of the Antiviral Drugs market in Ivory Coast is also being driven by the country's strong economic growth and increasing healthcare spending. The government has made significant investments in the healthcare sector in recent years, including the expansion of healthcare facilities and the provision of free healthcare for vulnerable populations. This has led to an increase in the availability of healthcare services, including antiviral drugs. Additionally, the country's growing middle class is also contributing to the growth of the market, as more people are able to afford healthcare services and medications.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.